We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Amneal Pharmaceuticals, Inc. ( NASDAQ: AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET ...

It's frustrating, but you're not alone! As we get older, our bodies don't respond the same way to weight loss efforts, and science has some explanations to offer. As we age we naturally tend to ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

The goal of body recomposition is to lose fat and gain muscle simultaneously, unlike the traditional approach of "bulking and cutting" in which you intentionally put on a lot of weight first ...